Revolution Medicines Inc Dossier
Qualitative Analysis
Business overview
Revolution Medicines, Inc. (NASDAQ: RVMD) is a Redwood City, California-based clinical-stage precision oncology company founded in 2014. The company is dedicated to developing novel targeted therapies for patients with RAS-addicted cancers, which represent a major driver of human malignancies. Revolution Medicines has pioneered a robust pipeline of active-state RAS inhibitors, known as RAS(ON) inhibitors, designed to suppress diverse oncogenic variants of RAS proteins. Its lead clinical candidate is daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor. The pipeline also includes elironrasib (RMC-6291), a mutant-selective RAS(ON) G12C inhibitor, and zoldonrasib (RMC-9805), a mutant-selective RAS(ON) G12D inhibitor, both of which are in active clinical development.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Aggressively advancing the clinical development of the company's RAS(ON) inhibitor pipeline, particularly lead candidate daraxonrasib (RMC-6236) and zoldonrasib (RMC-6291).
Expected impact: Establishment of a leading global targeted medicines franchise for RAS-addicted cancers.
Actively building out global commercial capabilities, infrastructure, and teams in preparation for the potential regulatory approval and market launch of lead candidate daraxonrasib.
Expected impact: Enables rapid and effective market entry and commercialization upon FDA approval.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides substantial non-dilutive capital to support the clinical development and potential commercialization of the RAS(ON) inhibitor pipeline, extending the company's cash runway.
Terms: Up to $2 billion in committed capital, consisting of $1.25 billion in synthetic royalties on future sales of daraxonrasib and $750 million in debt. Royalty Pharma receives worldwide royalties on future sales of daraxonrasib for 15 years.